The acquisition is expected to close in February, Zimmer Biomet said in a Jan. 5 news release. Along with the upfront cost, Zimmer Biomet could pay an additional $120 million subject to meeting regulatory and commercial milestones over three years.
Embody focuses on soft tissue healing, and its portfolio includes the Tapestry biointegrative implant for tendon healing and Tapestry RC implant for rotator cuff repair.
“Embody’s differentiated products and innovative pipeline in the area of sports medicine support our continued focus on and investment in high-growth markets and underscores our commitment to bringing meaningful new advances to patients and surgeons,” Bryan Hanson, president and CEO of Zimmer Biomet said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
